RCUS · Arcus Biosciences, Inc.
$28.42
-2.84% last session
End-of-day data · updated 2026-07-28
Market cap
$4B
Enterprise value
$3B
Trailing P/E
—
Forward P/E
-9.0
Dividend yield
—
Beta
0.80
Avg volume
1M
Employees
1K
2D change
—
5D change
-6.36%
10D change
1.72%
30D change
-10.19%
60D change
9.87%
MTD change
-3.73%
YTD change
16.83%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — RCUS
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-20
Latest call per bank · past 12 months
Morgan Stanley
Equal-Weight$22.00
-22.6% vs priceGoldman Sachs
Buy$34.00
+19.6% vs priceCitigroup
Buy$45.00
+58.3% vs priceWells Fargo
Equal-Weight$23.00
-19.1% vs priceBank of America
Neutral$26.00
-8.5% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-20 | HC Wainwright & Co. | Maintains | Buy | $32.00 → $45.00 |
| 2026-06-04 | LifeSci Capital | Initiates | Outperform | $0.00 → $46.00 |
| 2026-05-11 | Morgan Stanley | Maintains | Equal-Weight | $20.00 → $22.00 |
| 2026-05-07 | Goldman Sachs | Maintains | Buy | $30.00 → $34.00 |
| 2026-04-02 | Wedbush | Maintains | Outperform | $37.00 → $41.00 |
| 2026-03-05 | Citigroup | Maintains | Buy | $44.00 → $45.00 |
| 2026-03-02 | Leerink Partners | Maintains | Outperform | $36.00 → $49.00 |
| 2026-03-02 | HC Wainwright & Co. | Reiterates | Buy | $32.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 45 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 2.1% above the 50-day MA ($26.49).
- Price vs 200-day MA: Trading 17.5% above the 200-day MA ($23.03).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.29) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($9.06) and high ($31.08).
RCUS Price Chart
Loading chart for RCUS…
Fundamentals
About Arcus Biosciences, Inc.
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.